There's been a significant slowdown in influenza and COVID samples sent to CDC from other countries, which could impair pandemic preparedness and vaccine development ...
The Centers for Disease Control and Prevention holds patents on the use of Truvada for HIV prevention, according to advocates, who want Gilead Sciences to pay future and retroactive royalties to make ...
The CDC has increased its funding to help states and communities become better prepared to track and respond to infectious diseases. This year, the agency will award roughly $110 million, a $13 ...
For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...
Gilead Sciences Inc (NASDAQ:GILD) stock is trading lower during the premarket trading session on Wednesday. According to a Tuesday report in the Wall Street Journal, the Health and Human Services ...
Healthbeat on MSNOpinion
A public health horror story: If the zombies arrive on Halloween, will the CDC be there to respond?
In 2011, the Centers for Disease Control and Prevention’s Office of Public Health Preparedness and Response published a ...
Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on ...
According to CDC statistics, only 25% of the approximately 1.2 million Americans who could benefit from PrEP had prescriptions in 2020. As the Bay Area Reporter has previously reported, people of ...
Rusie LK, Orengo C, Burrell D, et al. PrEP initiation and retention in care over five years, 2012–2017: are quarterly visits too much? Clin Infect Dis 2018; 68:349–350. 2. Chan PA, Mena L, Patel R, et ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback